Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced on April 1, 2026 that its Compensation Committee granted non-qualified stock options for an aggregate of 36,000 shares to two newly hired employees under the 2022 Inducement Plan pursuant to Nasdaq Rule 5635(c)(4).

The options carry a $2.57 exercise price (closing price on the grant date), a 10-year term, and four-year vesting (25% after one year, remainder monthly over three years), subject to continued service.

News Market Reaction – ZNTL

+2.33%

17 alerts

+2.33% Session close to close

+9.6% Peak in 25 hr 25 min

$191.16M Market Cap

0.3x Rel. Volume

In the Apr 2 session, ZNTL gained 2.33%, reflecting a moderate positive market reaction. Argus tracked a peak move of +9.6% during that session. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details stock option inducement grants totaling 36,000 shares at an exercise price...

Analysis

This announcement details stock option inducement grants totaling 36,000 shares at an exercise price of $2.57, vesting over four years and tied to continued employment. It adds to a pattern of equity-based compensation alongside prior grants disclosed in recent Form 4 filings. In context of earlier updates on cash runway into late 2027 and key azenosertib milestones, investors may watch future clinical readouts and any additional equity awards or insider activity as indicators of ongoing execution.

Key Figures

Inducement options: 36,000 shares New hires: 2 employees Exercise price: $2.57 per share +3 more

6 metrics

Inducement options 36,000 shares Non-qualified stock options to two new employees

New hires 2 employees Recipients of inducement stock option grants

Exercise price $2.57 per share Equal to Nasdaq closing price on April 1, 2026

Option term 10 years Term of inducement stock options granted April 1, 2026

Initial vesting 25% Vests on first anniversary of vesting commencement date

Remainder vesting 75% over three years Equal monthly installments over subsequent three years

Historical Context

5 past events · Latest: Mar 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 26	Full-year results	Positive	-5.2%	Reported 2025 results and cash of $245.9M with runway into late 2027.
Mar 17	AACR posters	Positive	-7.9%	Announced two scientific posters on azenosertib and Cyclin E1 biomarkers at AACR.
Feb 18	Investor conferences	Neutral	+1.7%	Planned management participation in three investor conferences with webcasts.
Feb 03	Investor conference	Neutral	-9.6%	Announced participation in Guggenheim biotech summit fireside discussion.
Jan 06	Corporate update	Positive	+29.9%	Outlined 2026 milestones for azenosertib and reported $280.7M cash with runway.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent ZNTL news has often seen negative or mixed price reactions, even when updates highlighted cash runway and clinical progress, with only some corporate/milestone updates aligning positively.

Recent Company History

Over the last few months, ZNTL updates have focused on financial runway and the azenosertib program. A Jan 6 corporate update and 2026 milestones for DENALI and ASPENOVA coincided with a +29.93% move, while the Mar 26 full-year 2025 results and cash runway into late 2027 saw a -5.24% reaction. Announcements around AACR posters and investor conferences drew mixed to negative moves. Today’s inducement grants fit into an ongoing pattern of equity-based compensation and clinical-stage execution.

Key Terms

non-qualified stock options, Nasdaq Listing Rule 5635(c)(4), exercise price

3 terms

non-qualified stock options financial

"granted non-qualified stock options to purchase an aggregate of 36,000 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

Nasdaq Listing Rule 5635(c)(4) regulatory

"as an inducement material to each such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"The stock options have an exercise price of $2.57 per share, which is equal to the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Zentalis^® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on April 1, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 36,000 shares of the Company’s common stock to two newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual’s entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $2.57 per share, which is equal to the closing price of Zentalis’ common stock on The Nasdaq Global Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter.

Vesting of the stock options is subject to the employees’ continued service to Zentalis on each vesting date.

About Zentalis Pharmaceuticals
Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.​

For more information, please visit www.zentalis.com. Follow Zentalis on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.

Contact: 
Aron Feingold
VP, Investor Relations & Corporate Communications
ir@zentalis.com

FAQ

What did Zentalis (ZNTL) announce on April 1, 2026 about employee stock option grants?

Zentalis granted non-qualified options for an aggregate of 36,000 shares to two new hires. According to Zentalis, the grants were made under the 2022 Inducement Plan as inducements under Nasdaq Listing Rule 5635(c)(4).

What are the exercise price and term for the Zentalis (ZNTL) options granted April 1, 2026?

The options have a $2.57 exercise price and a 10-year term. According to Zentalis, $2.57 equals the closing Nasdaq price on the grant date and each option expires after ten years.

How do the Zentalis (ZNTL) stock options vest that were granted on April 1, 2026?

The options vest over four years: 25% after one year, then monthly over three years. According to Zentalis, vesting is contingent on the employees' continued service on each vesting date.

Why were the stock options granted under Zentalis' 2022 Inducement Plan (ZNTL)?

The grants were used as inducements for newly hired employees under Nasdaq Rule 5635(c)(4). According to Zentalis, the 2022 Inducement Plan is reserved for equity awards to new hires or returning employees.

How many employees received options in Zentalis' (ZNTL) April 1, 2026 grant and how many shares were awarded?

Two newly hired employees received options totaling 36,000 shares. According to Zentalis, the aggregate grant was split between the two hires under the 2022 Inducement Plan.